Resolving the controversies surrounding lymphatic mapping in breast cancer

Future Oncology

Volumn 4, Issue 5, 2008, Pages 681-688

  Bergkvist, Leif ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARCINOMA IN SITU; FALSE NEGATIVE RESULT; HUMAN; INTERMETHOD COMPARISON; INTRADUCTAL CARCINOMA; LYMPH FLOW; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAMMOGRAPHY; MORBIDITY; NEEDLE BIOPSY; POSTOPERATIVE CARE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENTINEL LYMPH NODE BIOPSY; TUMOR VOLUME;

BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; SENTINEL LYMPH NODE BIOPSY;

EID: 55249096484     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.4.5.681     Document Type: Review

References (85)

1. McMasters KM, Tuttle TM, Carlson DJ et al.: Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J. Clin. Oncol. 18, 2560-2566 (2000).
2. Jansen L, Doting MH, Rutgers EJ et al.: Clinical relevance of sentinel lymph nodes outside the axilla in patients with breast cancer. Br. J. Surg. 87, 920-925 (2000).
3. Yao MS, Kurland BF, Smith AH et al.: Internal mammary nodal chain drainage is a prognostic indicator in axillary node-positive breast cancer. Ann. Surg. Oncol. 14, 2985-2993 (2007).
4. Wouters MW, van Geel AN, Menke-Pluijmers M et al.: Should internal mammary chain (IMC) sentinel node biopsy be performed? Outcome in 90 consecutive non-biopsied patients with a positive IMC scintigraphy. Breast 17(2), 152-158 (2007).
5. Veronesi U, Marubini E, Mariani L et al.: The dissection of internal mammary nodes does not improve the survival of breast cancer patients. 30-year results of a randomised trial. Eur. J. Cancer 35, 1320-1325 (1999).
6. Palmer MK, Ribeiro GG: Thirty-four year follow up of patients with breast cancer in clinical trial of postoperative radiotherapy. Br. Med. J. (Clin. Res. Ed.) 291, 1088-1091 (1985).
7. van der Ploeg IM, Kroon BB, Antonini N et al.: Axillary and extra-axillary lymph node recurrences after a tumor-negative sentinel node biopsy for breast cancer using intralesional tracer administration. Ann. Surg. Oncol. 15, 1025-1031 (2008).
8. Mansel RE, Goyal A, Newcombe RG: Internal mammary node drainage and its role in sentinel lymph node biopsy: the initial ALMANAC experience. Clin. Breast Cancer 5, 279-284; discussion 285-286 (2004).
9. Clarke D, Newcombe RG, Mansel RE: The learning curve in sentinel node biopsy: the ALMANAC experience. Ann. Surg. Oncol. 11, S211-215 (2004).
10. McMasters KM, Wong SL, Chao C et al.: Defining the optimal surgeon experience for breast cancer sentinel lymph node biopsy: a model for implementation of new surgical techniques. Ann. Surg. 234, 292-299; discussion 299-300 (2001).
11. Celebioglu F, Sylvan M, Perbeck L et al.: Intraoperative sentinel lymph node examination by frozen section, immunohistochemistry and imprint cytology during breast surgery - a prospective study. Eur. J. Cancer 42, 617-620 (2006).
12. Grabau DA, Rank F, Friis E: Intraoperative frozen section examination of axillary sentinel lymph nodes in breast cancer. Apmis 113, 7-12 (2005).
13. Blumencranz P, Whitworth PW, Deck K et al.: Scientific Impact Recognition Award. Sentinel node staging for breast cancer: intraoperative molecular pathology overcomes conventional histologic sampling errors. Am. J. Surg. 194, 426-432 (2007).
14. Zakaria S, Degnim AC, Kleer CG et al.: Sentinel lymph node biopsy for breast cancer: how many nodes are enough? J. Surg. Oncol. 96, 554-559 (2007).
15. Schwartz GF, Giuliano AE, Veronesi U: Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19-22, 2001, Philadelphia, Pennsylvania. Cancer 94, 2542-2551 (2002).
16. Kim T, Giuliano AE, Lyman GH: Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer 106, 4-16 (2006).
17. Kuijt GP, Roumen RM: Second thoughts on sentinel lymph node biopsy in node-negative breast cancer. Br. J. Surg. 95, 310-311 (2008).
18. Zavagno G, De Salvo GL, Scalco G et al.: A randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann. Surg. 247, 207-213 (2008).
19. Veronesi U, Paganelli G, Viale G et al.: Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol. 7, 983-990 (2006).
20. Mansel RE, Fallowfield L, Kissin M et al.: Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J. Natl Cancer Inst. 98, 599-609 (2006).
21. Krag DN, Anderson SJ, Julian TB et al.: Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised Phase III trial. Lancet Oncol. 8, 881-888 (2007).
22. Goyal A, Newcombe RG, Chhabra A et al.: Morbidity in breast cancer patients with sentinel node metastases undergoing delayed axillary lymph node dissection(ALND) compared with immediate ALND. Ann. Surg. Oncol. 15, 262-267 (2008).
23. Schijven MP, Vingerhoets AJ, Rutten HJ et al.: Comparison of morbidity between axillary lymph node dissection and sentinel node biopsy. Eur. J. Surg. Oncol. 29, 341-350 (2003).
24. Schrenk P, Rieger R, Shamiyeh A et al.: Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. Cancer 88, 608-614 (2000).
25. Series SF, Winchester DJ, Martz CH et al.: Lymphedema after sentinel lymphadenectomy for breast carcinoma. Cancer 92, 748-752 (2001).
26. Husted Madsen A, Haugaard K, Soerensen J et al.: Arm morbidity following sentinel lymph node biopsy or axillary lymph node dissection: A study from the Danish Breast Cancer Cooperative Group. Breast 17(2), 138-147 (2007).
27. Wilke LG, McCall LM, Posther KE et al.: Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann. Surg. Oncol. 13, 491-500 (2006).
28. Chung MH, Ye W, Giuliano AE: Role for sentinel lymph node dissection in the management of large (> or = 5 cm) invasive breast cancer. Ann. Surg. Oncol. 8, 688-692 (2001).
29. Schule J, Frisell J, Ingvar C et al.: Sentinel node biopsy for breast cancer larger than 3 cm in diameter. Br. J. Surg. 94, 948-951 (2007).
30. Takei H, Kurosumi M, Yoshida T et al.: Current trends of sentinel lymph node biopsy for breast cancer - a surgeon's perspective. Breast Cancer 14, 362-370 (2007).
31. Wong SL, Chao C, Edwards MJ et al.: Accuracy of sentinel lymph node biopsy for patients with T2 and T3 breast cancers. Am. Surg. 67, 522-526; discussion 527-528 (2001).
32. Lelievre L, Houvenaeghel G, Buttarelli M et al.: Value of the sentinel lymph node procedure in patients with large size breast cancer. Ann. Surg. Oncol. 14, 621-626 (2007).
33. Leidenius MH, Krogerus LA, Toivonen TS et al.: Sentinel node biopsy is not sensible in breast cancer patients with large primary tumours. Eur. J. Surg. Oncol. 31, 364-368 (2005).
34. Goyal A, Newcombe RG, Mansel RE et al.: Sentinel lymph node biopsy in patients with multifocal breast cancer. Eur. J. Surg. Oncol. 30, 475-479 (2004).
35. Knauer M, Konstantiniuk P, Haid A et al.: Multicentric breast cancer: a new indication for sentinel node biopsy - a multi-institutional validation study. J. Clin. Oncol. 24, 3374-3380 (2006).
36. Kim HJ, Lee JS, Park EH et al.: Sentinel node biopsy in patients with multiple breast cancer. Breast Cancer Res. Treat. 109(3), 503-506 (2007).
37. Bergkvist L, Frisell J: Multicentre validation study of sentinel node biopsy for staging in breast cancer. Br. J. Surg. 92, 1221-1224 (2005).
38. Bergkvist L, Frisell J, Liljegren G et al.: Multicentre study of detection and false-negative rates in sentinel node biopsy for breast cancer. Br. J. Surg. 88, 1644-1648 (2001).
39. Madsen AH, Lauridsen MC, Garne JP et al.: Sentinel lymph node biopsy technique and multifocal breast cancer - the Aarhus experience. Acta Oncol. 46, 691-696 (2007).
40. Specht MC, Fey JV. Borgen PI et al.: Is the clinically positive axilla in breast cancer really a contraindication to sentinel lymph node biopsy? J. Am. Coll. Surg. 200, 10-14 (2005).
41. Gentilini O, Cremonesi M, Trifiro G et al.: Safety of sentinel node biopsy in pregnant patients with breast cancer. Ann. Oncol. 15, 1348-1351 (2004).
42. Keleher A, Wendt R, 3rd, Delpassand E et al.: The safety of lymphatic mapping in pregnant breast cancer patients using Tc-99m sulfur colloid. Breast J. 10, 492-495 (2004).
43. Celebioglu F, Frisell J, Danielsson R et al.: Sentinel node biopsy in non-palpable breast cancer and in patients with a previous diagnostic excision. Eur. J. Surg. Oncol. 33, 276-280 (2007).
44. Luini A, Galimberti V, Gatti G et al.: The sentinel node biopsy after previous breast surgery: preliminary results on 543 patients treated at the European Institute of Oncology. Breast Cancer Res. Treat. 89, 159-163 (2005).
45. Wong SL, Edwards MJ, Chao C et al.: The effect of prior breast biopsy method and concurrent definitive breast procedure on success and accuracy of sentinel lymph node biopsy. Ann. Surg. Oncol. 9, 272-277 (2002).
46. Estourgie SH, Valdes Olmos RA, Nieweg OE et al.: Excision biopsy of breast lesions changes the pattern of lymphatic drainage. Br. J. Surg. 94, 1088-1091 (2007).
47. Axelsson CK, Jonsson PE: Sentinel lymph node biopsy in operations for recurrent breast cancer. Eur. J. Surg. Oncol. (2007).
48. Port ER, Garcia-Etienne CA, Park J et al.: Reoperative sentinel lymph node biopsy: a new frontier in the management of ipsilateral breast tumor recurrence. Ann. Surg. Oncol. 14, 2209-2214 (2007).
49. Intra M, Trifiro G, Viale G et al.: Second biopsy of axillary sentinel lymph node for reappearing breast cancer after previous sentinel lymph node biopsy. Ann. Surg. Oncol. 12, 895-899 (2005).
50. No authors listed. Prognostic importance of occult axillary lymph node micrometastases from breast cancers. International (Ludwig) Breast Cancer Study Group. Lancet 335, 1565-1568 (1990).
51. Ryden L, Chebil G, Sjostrom L et al.: Determination of sentinel lymph node (SLN) status in primary breast cancer by prospective use of immunohistochemistry increases the rate of micrometastases and isolated tumour cells: analysis of 174 patients after SLN biopsy. Eur. J. Surg. Oncol. 33, 33-38 (2007).
52. Maaskant AJ, van de Poll-Frarrse LV, Voogd AC et al.: Stage migration due to introduction of the sentinel node procedure: a population-based study. Breast Cancer Res. Treat. PMID: 18259855 (2008) (Epub ahead of print).
53. Madsen AH, Jensen AR, Christiansen P et al.: Does the introduction of sentinel node biopsy increase the number of node positive patients with early breast cancer? A population based study form the Danish Breast Cancer Cooperative Group. Acta Oncol. 47, 239-247 (2008).
54. van der Heiden-van der Loo M, Bezemer PD, Hennipman A et al.: Introduction of sentinel node biopsy and stage migration of breast cancer. Eur. J. Surg. Oncol. 32, 710-714 (2006).
55. Yen TW, Hunt KK, Ross MI et al.: Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J. Am. Coll. Surg. 200, 516-526 (2005).
56. Zavagno G, Carcoforo P, Marconato R et al.: Role of axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. BMC Cancer 5, 28 (2005).
57. Xing Y, Foy M, Cox DD et al.: Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br. J. Surg. 93, 539-546 (2006).
58. Cox CE, Cox JM, White LB et al.: Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer. Ann. Surg. Oncol. 13, 483-490 (2006).
59. van Rijk MC, Nieweg OE, Rutgers EJ et al.: Sentinel node biopsy before neoadjuvant chemotherapy spares breast cancer patients axillary lymph node dissection. Ann. Surg. Oncol. 13, 475-479 (2006).
60. Luini A, Caldarella P, Gatti G et al.: The sentinel node biopsy under local anesthesia in breast cancer: advantages and problems, how the technique influenced the activity of a breast surgery department; update from the European Institute of Oncology with more than 1000 cases. Breast 16, 527-532 (2007).
61. Chagpar AB, Scoggins CR, Martin RC 2nd et al.: Prediction of sentinel lymph node-only disease in women with invasive breast cancer. Am. J. Surg. 192, 882-887 (2006).
62. Van Zee KJ, Manasseh DM, Bevilacqua JL et al.: A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann. Surg. Oncol. 10, 1140-1151 (2003).
63. Alkhatib W, Connor C, Fang F: Solitary positive sentinel lymph node accompanied by negative sentinel lymph node(s) is predictive of a negative completion axillary lymph node dissection. Am. J. Surg. 194, 856-858; discussion 858-859 (2007).
64. Park J, Fey JV, Naik AM et al.: A declining rate of completion axillary dissection in sentinel lymph node-positive breast cancer patients is associated with the use of a multivariate nomogram. Ann. Surg. 245, 462-468 (2007).
65. Hwang RF, Gonzalez-Angulo AM, Yi M et al.: Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection. Cancer 110, 723-730 (2007).
66. Poindexter NJ, Sabin A, Hunt KK et al.: Analysis of dendritic cells in tumor-free and tumor-containing sentinel lymph nodes from patients with breast cancer. Breast Cancer Res. 6, R408-R415 (2004).
67. Schule J, Bergkvist L, Hakansson L et al.: Down-regulation of the CD3-zeta chain in sentinel node biopsies from breast cancer patients. Breast Cancer Res. Treat. 74, 33-40 (2002).
68. Schule JM, Bergkvist L, Hakansson L et al.: CD28 expression in sentinel node biopsies from breast cancer patients in comparison with CD3-zeta chain expression. J. Transl. Med. 2, 45 (2004).
69. Kim R, Emi M, Tanabe K et al.: Immunobiology of the sentinel lymph node and its potential role for antitumour immunity. Lancet Oncol. 7, 1006-1016 (2006).
70. Bergkvist L, de Boniface J, Jonsson PE et al.: Axillary recurrence rate after negative sentinel node biopsy in breast cancer: three-year follow-up of the Swedish Multicenter Cohort Study. Ann. Surg. 247, 150-156 (2008).
71. Takei H, Suemasu K, Kurosumi M et al.: Recurrence after sentinel lymph node biopsy with or without axillary lymph node dissection in patients with breast cancer. Breast Cancer 14, 16-24 (2007).
72. Haid A, Knauer M, Koberle-Wuhrer R et al.: Medium-term follow-up data after sentinel node biopsy alone for breast cancer. Eur. J. Surg. Oncol. 32, 1180-1185 (2006).
73. Palesty JA, Foster JM, Hurd TC et al.: Axillary recurrence in women with a negative sentinel lymph node and no axillary dissection in breast cancer. J. Surg. Oncol. 93, 129-132 (2006).
74. Zavagno G, Carcoforo P, Franchini Z et al.: Axillary recurrence after negative sentinel lymph node biopsy without axillary dissection: a study on 479 breast cancer patients. Eur. J. Surg. Oncol. 31, 715-720 (2005).
75. Langer I, Marti WR, Gullet U et al.: Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases: prospective analysis of 150 patients after SLN biopsy. Ann. Surg. 241, 152-158 (2005).
76. Veronesi U, Galimberti V, Mariani L et al.: Sentinel node biopsy in breast cancer: early results in 953 patients with negative sentinel node biopsy and no axillary dissection. Eur. J. Cancer 41, 231-237 (2005).
77. Kokke MC, Jannink I, Barneveld PC et al.: Incidence of axillary recurrence in 113 sentinel node negative breast cancer patients: a 3-year follow-up study. Eur. J. Surg. Oncol. 31, 221-225 (2005).
78. de Kanter AY, Menke-Phrymers MM, Wouters MW et al.: 5-year follow-up of sentinel node negative breast cancer patients. Eur. J. Surg. Oncol. 32, 282-286 (2006).
79. Swenson KK, Mahipal A, Nissen MJ et al.: Axillary disease recurrence after sentinel lymph node dissection for breast carcinoma. Cancer 104, 1834-1839 (2005).
80. Naik AM, Fey J, Gemignani M et al.: The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures. Ann. Surg. 240, 462-468; discussion 468-471 (2004).
81. Imoto S, Wada N, Murakami K et al.: Prognosis of breast cancer patients treated with sentinel node biopsy in Japan. Jpn J. Clin. Oncol. 34, 452-456 (2004).
82. Torrenga H, Fabry H, van der Sijp JR et al.: Omitting axillary lymph node dissection in sentinel node negative breast cancer patients is safe: a long term follow-up analysis. J. Surg. Oncol. 88, 4-7; discussion 7-8 (2004).
83. van der Vegt B, Doting MH, Jager PL et al.: Axillary recurrence after sentinel lymph node biopsy. Eur. J. Surg. Oncol. 30, 715-720 (2004).
84. Reitsamer R, Peintinger F, Prokop E et al.: Sentinel lymph node biopsy alone without axillary lymph node dissection - follow up of sentinel lymph node negative breast cancer patients. Eur. J. Surg. Oncol. 29, 221-223 (2003).
85. Badgwell BD, Povoski SP, Abdessalam SF et al.: Patterns of recurrence after sentinel lymph node biopsy for breast cancer. Ann. Surg. Oncol. 10, 376-380 (2003).